| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2019 | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 300 PROFESSIONAL DR | GAITHERSBURG | MD | 20879-3419 | MONTGOMERY | USA | UG3DA048745 | Nalmefene Long-Acting Injectable (AP007) for the Treatment of Opioid Use Disorder | 000 | 1 | NIH | 9/13/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2019 | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 300 PROFESSIONAL DR | GAITHERSBURG | MD | 20879-3419 | MONTGOMERY | USA | UG3DA048745 | Nalmefene Long-Acting Injectable (AP007) for the Treatment of Opioid Use Disorder | 000 | 1 | NIH | 5/25/2022 | $0 |
| | 2022 | 2016 | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 300 PROFESSIONAL DR | GAITHERSBURG | MD | 20879-3419 | MONTGOMERY | USA | R01AI098911 | Development of a Manufacturing Process for a Novel TB Vaccine | 000 | 5 | NIH | 10/1/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $0 ) |
| | 2021 | 2019 | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 300 PROFESSIONAL DR | GAITHERSBURG | MD | 20879-3419 | MONTGOMERY | USA | UG3DA048745 | Nalmefene Long-Acting Injectable (AP007) for the Treatment of Opioid Use Disorder | 000 | 1 | NIH | 8/2/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $0 ) |
| | 2020 | 2019 | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 300 PROFESSIONAL DR | GAITHERSBURG | MD | 20879-3419 | MONTGOMERY | USA | UG3DA048745 | Nalmefene Long-Acting Injectable (AP007) for the Treatment of Opioid Use Disorder | 000 | 1 | NIH | 11/20/2019 | $0 |
| | 2020 | 2019 | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 300 PROFESSIONAL DR | GAITHERSBURG | MD | 20879-3419 | MONTGOMERY | USA | UG3DA048745 | Nalmefene Long-Acting Injectable (AP007) for the Treatment of Opioid Use Disorder | 002 | 1 | NIH | 9/16/2020 | $0 |
| | 2020 | 2019 | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 300 PROFESSIONAL DR | GAITHERSBURG | MD | 20879-3419 | MONTGOMERY | USA | UG3DA048745 | Nalmefene Long-Acting Injectable (AP007) for the Treatment of Opioid Use Disorder | 001 | 1 | NIH | 7/20/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $5,184,624 ) |
| | 2019 | 2019 | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 300 PROFESSIONAL DR | GAITHERSBURG | MD | 20879-3419 | MONTGOMERY | USA | UG3DA048745 | Nalmefene Long-Acting Injectable (AP007) for the Treatment of Opioid Use Disorder | 000 | 1 | NIH | 9/25/2019 | $6,354,906 |
| | 2019 | 2016 | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 300 PROFESSIONAL DR | GAITHERSBURG | MD | 20879-3419 | MONTGOMERY | USA | R01AI098911 | Development of a Manufacturing Process for a Novel TB Vaccine | 002 | 5 | NIH | 2/12/2019 | -$1,197,737 |
| | 2019 | 2016 | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 300 PROFESSIONAL DR | GAITHERSBURG | MD | 20879-3419 | MONTGOMERY | USA | R01AI098911 | Development of a Manufacturing Process for a Novel TB Vaccine | 001 | 5 | NIH | 1/7/2019 | $27,455 |
| | 2019 | 2016 | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 300 PROFESSIONAL DR | GAITHERSBURG | MD | 20879-3419 | MONTGOMERY | USA | R01AI098911 | Development of a Manufacturing Process for a Novel TB Vaccine | 005 | 5 | NIH | 6/18/2019 | $27,455 |
| | 2019 | 2016 | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 300 PROFESSIONAL DR | GAITHERSBURG | MD | 20879-3419 | MONTGOMERY | USA | R01AI098911 | Development of a Manufacturing Process for a Novel TB Vaccine | 004 | 5 | NIH | 6/6/2019 | -$27,455 |
| | 2019 | 2015 | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 300 PROFESSIONAL DR | GAITHERSBURG | MD | 20879-3419 | MONTGOMERY | USA | R01AI098911 | Development of a Manufacturing Process for a Novel TB Vaccine | 003 | 4 | NIH | 6/6/2019 | $27,455 |
| | 2019 | 2015 | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 300 PROFESSIONAL DR | GAITHERSBURG | MD | 20879-3419 | MONTGOMERY | USA | R01AI098911 | Development of a Manufacturing Process for a Novel TB Vaccine | 000 | 4 | NIH | 1/7/2019 | -$27,455 |
|
| Issue Date FY: 2016 ( Subtotal = $1,553,871 ) |
| | 2016 | 2016 | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC | 300 PROFESSIONAL DRIVE | GAITHERSBURG | MD | 20879 | MONTGOMERY | USA | R01AI098911 | Development of a Manufacturing Process for a Novel TB Vaccine | 000 | 5 | NIH | 7/14/2016 | $1,553,871 |
|
| Issue Date FY: 2015 ( Subtotal = $1,553,871 ) |
| | 2015 | 2015 | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC | 300 PROFESSIONAL DRIVE | GAITHERSBURG | MD | 20879 | MONTGOMERY | USA | R01AI098911 | Development of a Manufacturing Process for a Novel TB Vaccine | 000 | 4 | NIH | 6/29/2015 | $1,553,871 |
|
| Issue Date FY: 2014 ( Subtotal = $1,553,871 ) |
| | 2014 | 2014 | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC | 300 PROFESSIONAL DRIVE | GAITHERSBURG | MD | 20879 | MONTGOMERY | USA | R01AI098911 | Development of a Manufacturing Process for a Novel TB Vaccine | 000 | 3 | NIH | 6/13/2014 | $1,553,871 |
|
| Issue Date FY: 2013 ( Subtotal = $1,460,639 ) |
| | 2013 | 2013 | EMERGENT IMMUNOSOLUTIONS INC/BIOPORT CORP | 300 PROFESSIONAL DRIVE | GAITHERSBURG | MD | 20879 | MONTGOMERY | USA | R01AI098911 | Development of a Manufacturing Process for a Novel TB Vaccine | 001 | 2 | NIH | 7/22/2013 | $1,460,639 |
| | 2013 | 2012 | EMERGENT IMMUNOSOLUTIONS INC/BIOPORT CORP | 300 PROFESSIONAL DRIVE | GAITHERSBURG | MD | 20879 | MONTGOMERY | USA | R01AI098911 | Development of a Manufacturing Process for a Novel TB Vaccine | 000 | 1 | NIH | 3/7/2013 | $0 |
|
| Issue Date FY: 2012 ( Subtotal = $1,828,149 ) |
| | 2012 | 2012 | EMERGENT IMMUNOSOLUTIONS INC/BIOPORT CORP | 300 PROFESSIONAL DRIVE | GAITHERSBURG | MD | 20879 | MONTGOMERY | USA | U01AI078169 | DEVELOPMENT OF A NEXT GENERATION ANTHRAX VACCINE, AV7909 | 003 | 5 | NIH | 6/7/2012 | $246,331 |
| | 2012 | 2012 | EMERGENT IMMUNOSOLUTIONS INC/BIOPORT CORP | 300 PROFESSIONAL DRIVE | GAITHERSBURG | MD | 20879 | MONTGOMERY | USA | R01AI098911 | Development of a Manufacturing Process for a Novel TB Vaccine | 000 | 1 | NIH | 3/19/2012 | $1,111,100 |
| | 2012 | 2012 | EMERGENT IMMUNOSOLUTIONS INC/BIOPORT CORP | 300 PROFESSIONAL DRIVE | GAITHERSBURG | MD | 20879 | MONTGOMERY | USA | R01AI098911 | Development of a Manufacturing Process for a Novel TB Vaccine | 001 | 1 | NIH | 7/2/2012 | $442,771 |
| | 2012 | 2012 | EMERGENT IMMUNOSOLUTIONS INC/BIOPORT CORP | 300 PROFESSIONAL DRIVE | GAITHERSBURG | MD | 20879 | MONTGOMERY | USA | R01AI098911 | Development of a Manufacturing Process for a Novel TB Vaccine | 002 | 1 | NIH | 7/26/2012 | $1,553,871 |
| | 2012 | 2012 | EMERGENT IMMUNOSOLUTIONS INC/BIOPORT CORP | 300 PROFESSIONAL DRIVE | GAITHERSBURG | MD | 20879 | MONTGOMERY | USA | R01AI098911 | Development of a Manufacturing Process for a Novel TB Vaccine | 002 | 1 | NIH | 7/26/2012 | -$1,553,871 |
| | 2012 | 2011 | EMERGENT IMMUNOSOLUTIONS INC/BIOPORT CORP | 300 PROFESSIONAL DRIVE | GAITHERSBURG | MD | 20879 | MONTGOMERY | USA | U01AI078169 | DEVELOPMENT OF A NEXT GENERATION ANTHRAX VACCINE, AV7909 | 002 | 4 | NIH | 1/30/2012 | $15,062 |
| | 2012 | 2010 | EMERGENT IMMUNOSOLUTIONS INC/BIOPORT CORP | 300 PROFESSIONAL DRIVE | GAITHERSBURG | MD | 20879 | MONTGOMERY | USA | U01AI078169 | DEVELOPMENT OF A NEXT GENERATION ANTHRAX VACCINE, AV7909 | 000 | 3 | NIH | 1/18/2012 | $12,885 |
| | 2012 | 2008 | EMERGENT IMMUNOSOLUTIONS INC/BIOPORT CORP | 300 PROFESSIONAL DRIVE | GAITHERSBURG | MD | 20879 | MONTGOMERY | USA | U01AI078169 | DEVELOPMENT OF A NEXT GENERATION ANTHRAX VACCINE, AV7909 | 001 | 1 | NIH | 1/18/2012 | $0 |
|
| Issue Date FY: 2011 ( Subtotal = $294,927 ) |
| | 2011 | 2011 | EMERGENT IMMUNOSOLUTIONS INC/BIOPORT CORP | 300 PROFESSIONAL DRIVE | GAITHERSBURG | MD | 20879 | MONTGOMERY | USA | U01AI078169 | DEVELOPMENT OF A NEXT GENERATION ANTHRAX VACCINE, AV7909 | 000 | 4 | NIH | 8/4/2011 | $294,927 |
| | 2011 | 2009 | EMERGENT IMMUNOSOLUTIONS INC/BIOPORT CORP | 300 PROFESSIONAL DRIVE | GAITHERSBURG | MD | 20879 | MONTGOMERY | USA | U01AI070486 | ANTHRAX IMMUNE GLOBULIN TO PREVENT & TREAT ANTHRAX: ADVANCED PRODUCT DEVELOPMENT | 000 | 4 | NIH | 5/9/2011 | $0 |
|
| Issue Date FY: 2010 ( Subtotal = $3,587,578 ) |
| | 2010 | 2010 | EMERGENT IMMUNOSOLUTIONS INC/BIOPORT CORP | 300 PROFESSIONAL DRIVE | GAITHERSBURG | MD | 20879 | MONTGOMERY | USA | U01AI082224 | DEVELOPMENT OF A NEXT GENERATION ANTHRAX VACCINE, DMPA7909 | 002 | 2 | NIH | 9/29/2010 | $414,950 |
| | 2010 | 2010 | EMERGENT IMMUNOSOLUTIONS INC/BIOPORT CORP | 300 PROFESSIONAL DRIVE | GAITHERSBURG | MD | 20879 | MONTGOMERY | USA | U01AI078169 | DEVELOPMENT OF A NEXT GENERATION ANTHRAX VACCINE, AV7909 | 001 | 3 | NIH | 7/16/2010 | $291,478 |
| | 2010 | 2010 | EMERGENT IMMUNOSOLUTIONS INC/BIOPORT CORP | 300 PROFESSIONAL DRIVE | GAITHERSBURG | MD | 20879 | MONTGOMERY | USA | U01AI077910 | BIVALENT RECOMBINANT LHN BOTULINUM VACCINE (SEROTYPES A AND B) | 002 | 3 | NIH | 9/23/2010 | $0 |
| | 2010 | 2010 | EMERGENT IMMUNOSOLUTIONS INC/BIOPORT CORP | 300 PROFESSIONAL DRIVE | GAITHERSBURG | MD | 20879 | MONTGOMERY | USA | U01AI077910 | BIVALENT RECOMBINANT LHN BOTULINUM VACCINE (SEROTYPES A AND B) | 001 | 3 | NIH | 6/9/2010 | $399,412 |
| | 2010 | 2010 | EMERGENT IMMUNOSOLUTIONS INC/BIOPORT CORP | 300 PROFESSIONAL DRIVE | GAITHERSBURG | MD | 20879 | MONTGOMERY | USA | U01AI082224 | DEVELOPMENT OF A NEXT GENERATION ANTHRAX VACCINE, DMPA7909 | 001 | 2 | NIH | 9/15/2010 | $2,481,738 |
| | 2010 | 2009 | EMERGENT IMMUNOSOLUTIONS INC/BIOPORT CORP | 300 PROFESSIONAL DRIVE | GAITHERSBURG | MD | 20879 | MONTGOMERY | USA | U01AI077910 | BIVALENT RECOMBINANT LHN BOTULINUM VACCINE (SEROTYPES A AND B) | 000 | 2 | NIH | 11/20/2009 | $0 |
| | 2010 | 2009 | EMERGENT IMMUNOSOLUTIONS INC/BIOPORT CORP | 300 PROFESSIONAL DRIVE | GAITHERSBURG | MD | 20879 | MONTGOMERY | USA | U01AI082224 | DEVELOPMENT OF A NEXT GENERATION ANTHRAX VACCINE, DMPA7909 | 000 | 1 | NIH | 9/14/2010 | $0 |
| | 2010 | 2009 | EMERGENT IMMUNOSOLUTIONS INC/BIOPORT CORP | 300 PROFESSIONAL DRIVE | GAITHERSBURG | MD | 20879 | MONTGOMERY | USA | U01AI078169 | DEVELOPMENT OF A NEXT GENERATION ANTHRAX VACCINE, AV7909 | 000 | 2 | NIH | 12/11/2009 | $0 |
| | 2010 | 2009 | EMERGENT IMMUNOSOLUTIONS INC/BIOPORT CORP | 300 PROFESSIONAL DRIVE | GAITHERSBURG | MD | 20879 | MONTGOMERY | USA | U01AI070486 | ANTHRAX IMMUNE GLOBULIN TO PREVENT & TREAT ANTHRAX: ADVANCED PRODUCT DEVELOPMENT | 000 | 4 | NIH | 4/30/2010 | $0 |
|
|
